Hypothesis

Rapamycin and related mTORC1 inhibitors prolong life chiefly by lowering flux through the hexosamine biosynthetic pathway (HBP), which decreases UDP‑GlcNAc availability and thus reduces O‑GlcNAc modification of proteins that govern stress resistance and autophagy.

Mechanistic Rationale

mTORC1 activation drives glutamine uptake and fuels the rate‑limiting enzyme GFAT1, the gateway to HBP. When mTORC1 is inhibited, glutamine‑derived carbon is diverted away from UDP‑GlcNAc synthesis, lowering the substrate pool for O‑GlcNAc transferase (OGT). Reduced O‑GlcNAcylation of key regulators—such as AMPK, FOXO transcription factors, and the autophagy initiator ULK1—shifts them toward a more active, de‑modified state that enhances catabolic programs and stress resilience. This mirrors the ancestral famine response where nutrient scarcity naturally attenuates HBP flux, suggesting that rapamycin’s longevity effect is a pharmacological mimic of that state rather than a direct repair of damage.

Testable Predictions

1. HBP flux suppression is necessary for rapamycin’s lifespan extension. In models where HBP flux is genetically or pharmacologically forced high (e.g., overexpression of GFAT1 or supplementation with glucosamine), rapamycin will fail to increase median or maximal lifespan despite equivalent mTORC1 inhibition.
2. O‑GlcNAcylation status of specific targets predicts healthspan benefits. Mice treated with rapamycin will show decreased O‑GlcNAcylation of AMPK, FOXO3, and ULK1 in liver and muscle; rescuing O‑GlcNAcylation at these sites (via knock‑in of O‑GlcNAc–mimetic mutants) will blunt rapamycin‑induced autophagy markers and stress‑resistance phenotypes.
3. HBP flux lies downstream of mTORC1 in the longevity circuit. Activating HBP independently of mTORC1 (e.g., via constitutive GFAT1 expression) will shorten lifespan even when mTORC1 is inhibited, whereas reducing HBP flux (GFAT1 knock‑down or OGA overexpression) will extend lifespan similarly to rapamycin, and the effects will not be additive.

Experimental Approach

• Genetic models: Create liver‑specific GFAT1 overexpression mice and cross them with rapamycin‑treated cohorts; monitor lifespan, frailty index, and tissue‑specific O‑GlcNAcylome via lectin enrichment and mass spectrometry.
• Pharmacological rescue: Administer glucosamine or acetyl‑glucosamine to drinking water of rapamycin‑treated mice to elevate UDP‑GlcNAc; assess whether healthspan improvements (glucose tolerance, cardiac function, grip strength) are attenuated.
• Targeted mutational analysis: Generate knock‑in mice where O‑GlcNAc sites on AMPK (Ser485/491), FOXO3 (Ser644), and ULK1 (Ser555) are replaced with alanine (non‑modifiable) or aspartic acid (O‑GlcNAc–mimic). Compare rapamycin’s effect on autophagic flux (LC3‑II/p62) and stress resistance (oxidative challenge) across genotypes.
• Readouts: Measure mTORC1 activity (p‑S6K), HBP flux ( UDP‑GlcNAc levels via LC‑MS), O‑GlcNAcylation (RL2 immunoblot), autophagy (LC3‑II turnover, TFEB nuclear translocation), and standard aging phenotypes.

Falsifiability

If rapamycin extends lifespan equally in contexts where HBP flux is forcibly high or where O‑GlcNAcylation of the predicted targets is locked in a modified state, the hypothesis would be refuted. Conversely, a consistent loss of longevity benefit when HBP flux is maintained or when key sites remain O‑GlcNAcylated would support the claim that mTOR inhibition works by impersonating a nutrient‑scarcity signal through HBP suppression.